Population Health Research Institute

RELY - ABLE (Ongoing) 
Long Term Multi-Center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes.

< back

 The purposes of this study  is to evaluate the long-term safety of dabigatran etexilate and to assess the effect of a knowledge translation intervention on patient outcomes

Study Design: Treatment, Parallel assignment, Safety study

Intervention: Two blinded doses of Dabigatran etexilate

Length of Study: 28 months

# of Patients: 6,000

Patient Populations: Atrial fibrillation


Available upon study completion.

Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Stuart J. Connolly, Lars Wallentin, Michael D. Ezekowitz, John Eikelboom, Jonas Oldgren, Paul A. Reilly, Martina Brueckmann, Janice Pogue, Marco Alings, John V. Amerena, Alvaro Avezum, Iris Baumgartner, Andrzej J. Budaj, Jyh-Hong Chen, Antonio L. Dans, Harald Darius, Giuseppe Di Pasquale, Jorge Ferreira, Greg C. Flaker, Marcus D. Flather, Maria Grazia Franzosi, Sergey P. Golitsyn, David A. Halon, Hein Heidbuchel, Stefan H. Hohnloser, Kurt Huber, Petr Jansky, Gabriel Kamensky, Matyas Keltai, Sung Soon Kim, Chu-Pak Lau, Jean-Yves Le Heuzey, Basil S. Lewis, Lisheng Liu, John Nanas, Razali Omar, Prem Pais, Knud E. Pedersen, Leopoldo S. Piegas, Dimitar Raev, Pal J. Smith, Mario Talajic, Ru San Tan, Supachai Tanomsup, Lauri Toivonen, Dragos Vinereanu, Denis Xavier, Jun Zhu, Susan Q. Wang, Christine O. Duffy, Ellison Themeles and Salim Yusuf. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation 2013; 128: 237-243. (Originally published online June 14, 2013). 
Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca